Experimental Polymerase Inhibitor Lowers HCV Viral Load Fast
Share
Follow Us
Hepatitis C Virus Polymerase Inhibitor VX-222 Reduced Viral Levels Over Three Days In Phase 1b Trial
In conjunction with an oral presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from a Phase 1b clinical trial of the investigational oral hepatitis C virus (HCV) polymerase inhibitor, VX-222. In the trial, treatment with VX-222 for three days was well-tolerated, with all adverse events being mild to moderate in severity.
Continue reading this entire article:
http://www.thestreet.com/story/10726924/1/hepatitis-c-virus-polymerase-inhibitor-vx-222-reduced-viral-levels-over-three-days-in-phase-1b-trial.html?cm_ven=GOOGLEFI
